The study met its primary endpoint of decitabine exposure equivalence of five-day dosing between orally administered ASTX727 and intravenous decitabine as per the protocol analysis plan with a high degree of confidence.
Safety observations were similar to those observed with IV decitabine.
The full data will be presented on June 10 as part of EHA2022.
Astex plans to file a Marketing Authorization Application with the European Medicines Agency and similar applications in other countries where IV decitabine is indicated for the treatment of AML.
Based on the data from the ASCERTAIN clinical program, the oral decitabine and cedazuridine fixed-dose combination is also being investigated in combination with other agents in hematological malignancies.
The first of these studies is investigating the all-oral combination of decitabine and cedazuridine with venetoclax for the treatment of AML.
Oral decitabine and cedazuridine fixed-dose combination is approved as Inqovi in the US and Canada for the treatment of intermediate and high-risk myelodysplastic syndromes, including chronic myelomonocytic leukemia and is the only approved oral hypomethylating agent that has demonstrated equivalent exposure to its IV form.
Commercialization of Inqovi in the US and Canada for the above indication is conducted by Taiho Oncology, Inc., and by Taiho Pharma Canada, Inc., respectively.
Astex, Otsuka and Taiho are all members of the Otsuka group of companies.
The ASCERTAIN AML clinical trial was designed as a randomized crossover study comparing oral decitabine and cedazuridine (100mg) fixed-dose combination tablet given once daily for five days on a 28-day cycle to IV decitabine (20mg/m2) administered as a daily 1-hour infusion for five days on a 28-day cycle, in the first 2 cycles in AML patients who were unfit to receive intensive chemotherapy.
Patients continued to receive oral decitabine and cedazuridine from cycle 3 onwards.
The primary endpoint for the study was total five-day decitabine area-under-the-curve equivalence of oral decitabine and cedazuridine and IV decitabine.
ASTX727 is an orally administered, fixed dose combination of the approved anti-cancer DNA hypomethylating agent, decitabine, together with cedazuridine,2 an inhibitor of cytidine deaminase.
By inhibiting cytidine deaminase in the gut and the liver, ASTX727 is designed to allow for oral delivery of decitabine over five days in a given cycle to achieve comparable systemic exposure to IV decitabine administered over five days.
ASTX727 has been evaluated in a phase 1/2 pharmacokinetics-guided dose escalation and dose confirmation study, and a phase 3 exposure equivalence study in patients with MDS and CMML.
The phase 1 and phase 2 clinical study results have been published in Lancet Haematology and Blood, respectively, and the phase 3 results have been presented at the American Society of Hematology annual meeting in December 20196 and the International Congress on Myelodysplastic Syndromes in September 2021.
Astex is also expanding the evaluation of decitabine - cedazuridine combinations through a program of investigator-sponsored trials.
ASTX727 is an investigational compound and is not currently approved in any country other than the US, Canada, and Australia.
In the US, Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval